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Review Article
Corticosteroid Administration to Prevent
Complications of Anterior Cervical Spine
Fusion: A Systematic Review
Shayan Abdollah Zadegan, MD1, Seyed Behnam Jazayeri, MD1,
Aidin Abedi, MD1, Hirbod Nasiri Bonaki, MD1,
Alexander R. Vaccaro, MD, PhD2, and Vafa Rahimi-Movaghar, MD1
Abstract
Study Design: Systematic review.
Objectives: Anterior cervical approach is associated with complications such as dysphagia and airway compromise. In this study,
we aimed to systematically review the literature on the efficacy and safety of corticosteroid administration as a preventive
measure of such complications in anterior cervical spine surgery with fusion.
Methods: Following a systematic literature search of MEDLINE, Embase, and Cochrane databases in July 2016, all comparative
human studies that evaluated the effect of steroids for prevention of complications in anterior cervical spine surgery with fusion
were included, irrespective of number of levels and language. Risk of bias was assessed using MINORS (Methodological Index for
Non-Randomized Studies) checklist and Cochrane Back and Neck group recommendations, for nonrandomized and randomized
studies, respectively.
Results: Our search yielded 556 articles, of which 9 studies (7 randomized controlled trials and 2 non–randomized controlled
trials) were included in the final review. Dysphagia was the most commonly evaluated complication, and in most studies, its
severity or incidence was significantly lower in the steroid group. Although prevertebral soft tissue swelling was less commonly
assessed, the results were generally in favor of steroid use. The evidence for airway compromise and length of hospitalization was
inconclusive. Steroid-related complications were rare, and in both studies that evaluated the fusion rate, it was comparable
between steroid and control groups in long-term follow-up.
Conclusions: Current literature supports the use of steroids for prevention of complications in anterior cervical spine surgery
with fusion. However, evidence is limited by substantial risk of bias and small number of studies reporting key outcomes.
Keywords
cervical vertebrae, diskectomy, intervertebral disc, spinal fusion, steroids
Introduction
The anterior approach to the cervical spine using
Smith-Robinson technique has been commonly used for the
treatment of cervical discopathies.1,2 Although the anterior
approach is believed to be a relatively safe and effective proce-
dure, it has been associated with complications such as dyspha-
gia, dysphonia, airway compromise, and other tissue injuries.3-6
Dysphagia is an unpleasant condition and the most common
complication after anterior cervical approach with a reported
incidence rate of 1% to 79%, starting early in the postoperative
course.7-9 Although the etiology of dysphagia after anterior
cervical spine surgery is not fully understood and there are many
discrepancies in the findings of various studies, some factors
such as local tissue edema, recurrent laryngeal nerve palsy,
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retraction of midline structures during the surgery, and prever-
tebral soft tissue swelling (PSTS) have been proposed.7,10
Airway compromise is the most serious complication,
associated with pharyngeal edema, as well as hematoma,
angioedema, cerebrospinal fluid leak, and graft displace-
ment.11-16 Although a rare complication, airway compromise
is life-threatening as it could lead to reintubation, tracheost-
omy, or death.5,17
Corticosteroids are known anti-inflammatory agents that
inhibit the production of inflammatory prostaglandins and cyto-
kines. Since major adverse outcomes after anterior approach are
attributable to pharyngeal edema, it has been assumed that ster-
oids can reduce the incidence of complications.5 The aim of this
systematic review is to evaluate the current evidence regarding
the efficacy and safety of steroids in reducing the complications
of the anterior cervical spine surgery.
Methods
Protocol
This systematic review was designed according to the guide-
lines of Cochrane Handbook for Systematic Reviews of
Interventions (v. 5.1.0),18 method guideline for systematic
reviews in the Cochrane Back and Neck (CBN) group
[formerly Cochrane Back Review Group (CBRG)],19,20 and the
Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA)21-23 statement.
Eligibility Criteria
We included all studies with a control group including rando-
mized controlled trials (RCTs), controlled clinical trials,
cohort studies, and case-control studies. The target population
was patients of any age who underwent anterior cervical dis-
cectomy and fusion (ACDF) or anterior cervical corpectomy
and fusion with one- or multiple-level fusion and received
corticosteroids to prevent complications following the sur-
gery. We excluded studies that used cervical epidural steroid
injections as a diagnostic or therapeutic modality to relieve
radiculopathy or neck pain before the surgery. Animal studies
were also excluded.
Literature Search and Information Sources
We performed a systematic search of the literature on July 10,
2016, using the following electronic databases without any
restrictions on language or date of publications: MEDLINE
(via OvidSP and PubMed), Embase, and Cochrane EBM
(CENTRAL, DSR, and DARE). The complete search strategy
is presented in the appendix. Main search keywords were
“anterior,” “cervical vertebrae,” “cervical,” “neck,”
“intervertebral disc,” “spinal decompression,” “disc degener-
ation,” “disc displacement,” “disc herniation,”
“radiculopathy,” “myelopathy,” “spinal fusion,” “arthrodesis,”
“discectomy,” “glucocorticoids,” and “steroids.” Unpublished
records were not considered in this review.
Study Selection
Two authors (SAZ and SBJ) screened all titles and abstracts
independently. Full texts of relevant articles were obtained and
assessed for eligibility. To select the articles, we used a discus-
sion and consensus method at each step, and in case of dis-
agreement, a third reviewer (AA) was consulted. We also
screened the reference lists of included articles and relevant
reviews for possible inclusions.
Data Items and Collection Process
Two independent reviewers (SAZ and SBJ) used a predeter-
mined form to extract the following information: study design,
type of anterior procedure, demographic information, number
of operated levels, inclusion/exclusion criteria for each study,
dosage of the corticosteroid drug, and outcome variables. The
rate of disagreement between the 2 extractors was 1%.
Outcome variables considered in this review were dyspha-
gia/odynophagia, PSTS, airway compromise, length of hospital
stay, steroid-related complications, and fusion rate.
Risk of Bias
The risk of bias was independently assessed by 2 authors (SAZ
and SBJ). Disagreements were resolved with consensus or con-
sultation with a third reviewer (AA). For randomized studies,
we used the 13-item criteria recommended by the Cochrane
Back and Neck (CBN).19,20 This tool contains 5 domains of
bias, including selection bias (criteria 1, 2, and 9), performance
bias (criteria 3, 4, 10, and 11), detection bias (criteria 5 and 12),
attrition bias (criteria 6 and 7), and reporting bias (criterion 8).
There is also a 13th criterion, which covers any potential bias
that is not detected with previous items.20 For nonrandomized
studies, the 12-item criteria of Methodological Index for Non-
Randomized Studies (MINORS) were used.24 Each criterion is
scored from 0 to 2, and the highest possible score for compara-
tive studies is 24. This tool is proved to be valid and reliable to
evaluate interventional studies.24-26
A pilot test of the risk of bias assessment was performed on a
set of similar articles. The Review Manager (RevMan) Version
5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014) was used for assessment of the risk of bias
and production of related tables.
Data Synthesis
Meta-analysis was not feasible due to the heterogeneity of
studies.
Results
Study Selection
Our search yielded 556 results. Six additional titles were iden-
tified through hand-searching of the reference lists (Figure 1).
Of the 31 full-text articles included in the primary screening
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stage, 9 studies (total population: 246414) were eligible for
further consideration: 7 RCTs16,27-32 and 2 nonrandomized
studies (one cohort33 and one case-control study34). The other
22 articles were excluded because they were case reports,13,35-39
studies without a control group for steroid,40-45 seminar
abstracts,46-48 reviews,49,50 commentaries,51,52 or studies without
sufficient data on steroid use.53-55 Table 1 shows characteristics
of the included studies.
Risk of Bias
We assessed the risk of bias for 7 randomized studies with CBN
criteria (Figure 2). The 2 extractors primarily disagreed on 14
out of 91 items, all of which were consequently resolved
through discussion and consensus. Allocation concealment,
random sequence generation, and blinding (especially person-
nel and outcome assessors) were reported in less than 50% of
the trials (Figure 3).
We used MINORS tool for the 2 nonrandomized studies
(Figure 4). Of the total 24 items, 4 items required further dis-
cussion and consultation with a third reviewer. Blind evalua-
tion of the endpoints (item 5), loss to follow-up (item 7), and
prospective calculation of the study size (item 8) were not
addressed in both studies.
Outcomes
A detailed summary of the outcome measures is presented in
Table 2.
Dysphagia/Odynophagia
In this series of studies, main assessment tools for dysphagia/
odynophagia were the following:
1. Bazaz scale, which has 4 grades including none (no
dysphagia), mild (rare episodes of dysphagia with solid
food), moderate (occasional difficulty swallowing
foods such as bread or meat), and severe (frequent dys-
phagia with liquids and majority of foods).8 The Bazaz
scale has been widely used because of its simplicity;
however, it has never been validated.56 Among included
studies, Song et al30 and Koreckij et al34 used this scale,
and Edwards et al32 applied a modified version.
2. Eating Assessment Tool (EAT-10), a 10-item question-
naire with 0 to 4 points for each item (0 ¼ no problem,
4¼ severe problem) and maximum total of 40 points. A
total score greater than 3 is indicative of dysphagia.57
Koreckij et al34 used this tool besides the Bazaz scale.
3. Functional Outcome Swallowing Scale (FOSS) was
administered in one study by Jeyamohan et al.31 This
scale defines different stages for dysphagia ranging
from asymptomatic (stage 0) to non–oral feeding for
all nutrition (stage V).58
4. The Visual Analogue Scale (VAS) was used by Lee
et al16 and Nam et al29 for odynophagia.
Five RCTs reported that intravenous or local corticosteroids
significantly reduce dysphagia after anterior spinal sur-
gery.16,27,30-32 Pedram et al27 performed fiber-optic examina-
tion of the oropharynx, the hypopharynx, and the larynx. They
found that pharyngolaryngeal lesions were significantly more
severe in the control group during the first 36 hours after sur-
gery. Lee et al16 reported a lower VAS for odynophagia imme-
diately after surgery and during the first 2 weeks. Song at al30
monitored dysphagia with the Bazaz scale for the first 5 days
after surgery. Although the severity of dysphagia was the same
between the 2 groups in the first day, it was significantly
reduced in the steroid group in postoperative days 2 to 5. Simi-
larly, Edwards et al32 found no significant difference in the
modified Bazaz scale between steroid and control groups in
the first day postoperative, but afterwards, a significant reduc-
tion of symptoms occurred in the steroid group, which
remained through the 28 days of follow-up. Jeyamohan
et al,31 in a long-term follow-up (24 months) by FOSS, showed
that the severity of dysphagia is significantly lower in the ster-
oid group during the first month.
Of the 2 remaining RCTs, the one by Emery et al28 did not
have data regarding the swallowing problems, and the other by
Nam et al29 showed no significant difference in VAS scores for
odynophagia between the control, low-dose, and high-dose ster-
oid groups during the first 5 days after surgery. Their study was
the only one that had a population of pure one-level procedure,
while all other studies also included multilevel procedures.
Both the nonrandomized studies found positive effects of
steroids on reducing the incidence or severity of dysphagia.
Figure 1. PRISMA flow diagram.
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Cancienne et al33 in a cohort of 245754 patients showed that
incidence of dysphagia is lower within 90 days postoperatively
in patients treated with steroids. However, this finding was only
significant in ACDF 3-level fusion. Koreckij et al34 reported
a significant reduction in severity of dysphagia with EAT-10
and Bazaz scale at 1.5- and 3-month follow-up.
Prevertebral Soft Tissue Swelling
Only 4 of the included studies reported PSTS and there were
variations in their assessment methods. Lee et al16 calculated
the ratio of the anteroposterior diameter of each vertebral body
to the prevertebral soft tissue thickness in lateral radiographs of
cervical spine and reported a mean percentage of PSTS at C3-5
as PSTS index. Koreckij et al34 used the same method; the only
difference was that the PSTS index was calculated for C3-7.
Nam et al29 measured the prevertebral soft tissue density, an
area of the prevertebral soft tissue (in cm2) from the lower
border of C1 to the upper end plate of C7 in lateral radiographs.
Song et al30 measured the diameter of prevertebral tissue (in
mm) in lateral view.
The effect of steroid administration on PSTS was concor-
dant with the findings for dysphagia. Nam et al29 found no
significant difference in PSTS among groups within 5 days
postoperative. Lee et al16 and Song et al30 found significant
reduction in PSTS during the 2-week and 1-week follow-ups,
respectively. Similar to the results for dysphagia, Song et al30
reported a nonsignificant difference just for the first day post-
operative and a significant effect afterwards.
The only discordance between the results of dysphagia
assessment and PSTS was reported in the case-control study
by Koreckij et al,34 where they found no significant difference
in PSTS but a significant reduction of dysphagia between the
steroid and control groups.
Airway Compromise
The results for this outcome were very limited and poorly
reported. Emery et al28 used delayed extubation (>1day) as
an indicator of airway compromise and found no significant
difference between the control and steroid groups. Edwards
et al32 reported no adverse airway events (prolonged intuba-
tion, reintubation, or readmission for breathing difficulty) in
the steroid group and only one readmission for breathing dif-
ficulty in the control group, which was not statistically signif-
icant. Nam et al29 conducted VAS score for dyspnea. Although
they reported no significant effect of steroids on reduction of
dysphagia and PSTS, dyspnea was significantly reduced in the
Figure 2. Summary of risk of bias for randomized studies (the 13-item
criteria of the Cochrane Back and Neck group): review authors’
judgments about each risk of bias items for each included study. Plus
sign (green): low risk; Minus sign (red): high risk; Question mark
(yellow): unclear risk of bias.
Figure 3. Summary of risk of bias for randomized studies (the 13-item
criteria of the Cochrane Back and Neck group): review authors’
judgments about each risk of bias items across all included studies.
Figure 4. Summary of risk of bias for nonrandomized studies (MIN-
ORS criteria): review authors’ judgments about each risk of bias items
for each included study. 0: Not reported; 1: Reported but inadequate;
2: Reported and adequate.
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steroid group during the first 2 days postoperative. However,
there was no significant difference within the third to the fifth
days postoperative.
Length of Hospital Stay
Both RCTs reporting hospitalization period found no differ-
ence between the steroid and control groups.28,32 In contrast,
both nonrandomized studies proved a significantly shorter hos-
pital stay with steroid treatment.33,34
Postoperative Steroid Need
This outcome was defined as the proportion of patients who
required treatment with corticosteroids in the control group or
required extra doses of steroid, additional to the main protocol,
in the steroid group. Three studies reported this outcome to be
higher in the control group compared with the steroid group, as
follows: Pedram et al27 (55% vs 0%, P < .0001), Jeyamohan
et al31 (14.3% vs 1.8%), and Edwards et al32 (17.4% vs 3.7%,
P > .05).
Steroid-Related Complications
Song et al30 followed the patients for 3 months for complica-
tions such as peptic ulcer disease or operation site infections
and reported no complications. Likewise, Edwards et al32
found no infection, delayed healing, or diabetes. Combined
rates of infection and wound breakdown were measured by
Cancienne et al33 within 90 days postoperative. There was no
significant difference between the control and steroid groups
(1.6% vs 1.7%, respectively).
Fusion
Only 2 studies reported fusion rate. Lee et al16 observed com-
plete fusion at the latest follow-up (range 16-32 months) in
the lateral radiographs and computed tomography scans of the
patients treated with steroid, while they found one nonunion
in the control group. Jeyamohan et al31 performed computed
tomography scans at 6, 12, and 24 months postoperation. The
fusion rate was significantly lower in the steroid group com-
pared with the control at the 6-month follow-up (39.5% vs
60%, respectively), whereas this difference disappeared at
subsequent follow-ups (at 24 months, 92.7% vs 95.2%,
respectively).
Discussion
In this study, we reviewed the current evidence of steroid use in
anterior cervical spine surgery. Seven RCTs, one case-control
study, and one cohort study were included. The risk of bias
assessment showed that the quality of studies was generally
low, since both the nonrandomized studies were retrograde and
only 2 out of 7 randomized studies had acceptable method of
randomization.
Dysphagia significantly decreased with corticosteroids. This
finding was confirmed by all studies except the one performed
by Nam et al,29 in which they reported no significant difference
between the control and 2 steroid groups with different doses.
This may be due to their limited inclusion criteria that only
recruited patients with 1-level ACDF and excluded the proce-
dures on 2 or more levels. Cancienne et al33 found significant
effects of steroids only in ACDF 3 levels; in contrast, Lee
et al16 showed that dysphagia was significantly lowered by
steroids in 1- or 2-level ACDF. Despite some controversies,
all studies proved steroids to be beneficial in prevention of
dysphagia after anterior cervical procedures for more than 2
levels of fusion. This discrepancy implies the importance of
steroid trials comparing the outcomes between single- and mul-
tilevel procedures. Furthermore, since there is no sufficient
evidence on validity of most of the measures of dysphagia that
were used in these studies, their findings must be interpreted
with caution.
PSTS and airway compromise were reported in less than
50% of studies. PSTS was generally in accordance with find-
ings of dysphagia. Airway compromise is not a common com-
plication and was only reported in 3 studies. There was a vast
variation in assessment methods and the results. Surprisingly,
although Nam et al29 determined no significant effect of ster-
oids on reduction of dysphagia and PSTS, they reported a sig-
nificantly lower VAS score for dyspnea in steroid group. The
other 2 studies found no significant difference between the
steroid group and controls in their assessments for airway
compromise.28,32
Two major concerns regarding the use of corticosteroids are
steroid-related complications and reduced/delayed fusion. In
those few studies that addressed these outcomes, no complica-
tions or long-term reduction of fusion rates were reported.
However, as reported by Jeyamohan et al,31 the fusion rate was
significantly delayed in the steroid group at the 6-month
follow-up. As the current evidence is not enough, it is neces-
sary to appraise the effect of steroids on fusion rate in the
forthcoming studies with long-term designs.
The form, dose, and type of corticosteroid drug, as well as the
methods of outcome evaluation were different in the included
studies. This heterogeneity made the data pooling and meta-
analysis impossible. Further clinical trials with appropriate
design and sample size are needed to reach a definite conclusion.
Conclusion
Current literature consistently supports the use of steroids for
prevention of complication such as dysphagia in patients
undergoing anterior cervical spine surgery with fusion. How-
ever, these findings are limited by poor methodological quality
of the studies, particularly by the indeterminate quality of the
outcome measurement instruments. Furthermore, lack of com-
parisons between single- and multilevel surgeries and limited
number of steroid trials that evaluate the fusion rate, airway
compromise, and PSTS are the areas of concern that are rec-
ommended to be addressed in future studies.
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Search Strategy
PubMed. (Anterior) AND (“Cervical Vertebrae”[Mesh]
OR “Neck”[Mesh] OR cervical OR neck) AND
(“Diskectomy”[Mesh] OR “Decompression, Surgical”[Mesh]
OR “Intervertebral Disc”[Mesh] OR “Intervertebral Disc
Degeneration”[Mesh] OR “Intervertebral Disc Displace-
ment”[Mesh] OR “Discitis”[Mesh] OR “Radiculopathy”[Mesh]
OR “Spinal Cord Diseases”[Mesh] OR discectomy OR diskect-
omy OR decompression OR corpectomy OR radiculopath* OR
myelopath* OR radiculomyelopath* OR radiculo-myelopath*
OR myeloradiculopath* OR myelo-radiculopath* OR diskitis
OR discitis OR discopath* OR ((disc* OR disk*) AND (degen-
erat* OR displace* OR hernia*)) OR “Spinal Fusion”[Mesh]
OR “Arthrodesis”[Mesh] OR fusion OR arthrodesis) AND
(“Glucocorticoids”[Mesh] OR “Adrenal Cortex Hormo-
nes”[Mesh] OR “Steroids”[Mesh] OR “Dexamethasone”[Mesh]
OR “Betamethasone”[Mesh] OR “Hydrocortisone”[Mesh]
OR “Cortisone”[Mesh] OR “Prednisolone”[Mesh] OR
“Methylprednisolone”[Mesh] OR “Methylprednisolone
Hemisuccinate”[Mesh] OR “Triamcinolone”[Mesh] OR
“Triamcinolone Acetonide”[Mesh] OR “Budesonide”[Mesh]
OR “Fludrocortisone”[Mesh] OR “Fluprednisolone”[Mesh]
OR “Paramethasone”[Mesh] OR glucocortic* OR gluco-cortic*
OR corticosteroid* OR cortico-steroid* OR corticoid* OR ster-
oid* OR corticotropin OR dexamethason* OR dexametason*
OR betamethason* OR betametason* OR hydrocortison* OR
cortison* OR predniso* OR methylpredniso* OR methyl-pre-
dniso* OR triamcinolon* OR budesonid* OR fludrocortison*
OR fluprednisolon* OR paramethason*)
Embase
#1. anterior
#2. ‘cervical spine’/exp
#3. ‘neck’/exp
#4. cervical
#5. neck
#6. ‘cervical spine’/exp OR ‘neck’/exp OR cervical OR
neck
#7. ‘intervertebral diskectomy’/exp
#8. ‘spinal cord decompression’/exp
#9. ‘intervertebral disk’/exp
#10. ‘intervertebral disk degeneration’/exp
#11. ‘intervertebral disk hernia’/exp
#12. ‘radiculopathy’/exp
#13. ‘cervical myelopathy’/exp
#14. Discectomy
#15. Diskectomy
#16. Decompression
#17. corpectomy
#18. radiculopath*
#19. myelopath*
#20. radiculomyelopath*
#21. ‘radiculo myelopath*’
#22. myeloradiculopath*
#23. ‘myelo radiculopath*’
#24. discopath*
#25. ‘diskitis’/exp
#26. Diskitis
#27. Discitis
#28. disc* OR disk*
#29. degenerat* OR displace* OR hernia*
#30. disc* OR disk* AND (degenerat* OR displace* OR
hernia*)
#31. ‘anterior spine fusion’/exp
#32. fusion
#33. Arthrodesis
#34. ‘intervertebral diskectomy’/exp OR ‘spinal cord
decompression’/exp OR ‘intervertebral disk’/exp OR ‘inter-
vertebral disk degeneration’/exp OR ‘intervertebral disk
hernia’/exp OR ‘radiculopathy’/exp OR ‘cervical myelopa-
thy’/exp OR discectomy OR diskectomy OR decompression
OR corpectomy OR radiculopath* OR myelopath* OR radi-
culomyelopath* OR ‘radiculo myelopath*’ OR myeloradi-
culopath* OR ‘myelo radiculopath*’ OR discopath* OR
‘diskitis’/exp OR diskitis OR discitis OR (disc* OR disk*
AND (degenerat* OR displace* OR hernia*)) OR ‘anterior
spine fusion’/exp OR fusion OR arthrodesis
#35. ‘glucocorticoid’/exp
#36. ‘steroid’/exp
#37. ‘corticosteroid’/exp
#38. ‘dexamethasone’/exp
#39. ‘betamethasone’/exp
#40. ‘hydrocortisone’/exp
#41. ‘cortisone’/exp
#42. ‘prednisolone’/exp
#43. ‘methylprednisolone’/exp
#44. ‘methylprednisolone sodium succinate’/exp
#45. ‘triamcinolone’/exp
#46. ‘triamcinolone acetonide’/exp
#47. ‘budesonide’/exp
#48. ‘fludrocortisone’/exp
#49. ‘fluprednisolone’/exp
#50. ‘paramethasone’/exp
#51. glucocortic*
#52. ‘gluco cortic*’
#53. corticosteroid*
#54. ‘cortico steroid*’
#55. corticoid*
#56. steroid*
#57. Corticotropin
#58. dexamethason*
#59. dexametason*
#60. betamethason*
#61. betametason*
#62. hydrocortison*
#63. cortison*
#64. predniso*
#65. methylpredniso*
#66. ‘methyl predniso*’
#67. triamcinolon*
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#68. budesonid*
#69. fludrocortison*
#70. fluprednisolon*
#71. paramethason*
#72. ‘glucocorticoid’/exp OR ‘steroid’/exp OR ‘corticoster-
oid’/exp OR ‘dexamethasone’/exp OR ‘betamethasone’/exp
OR ‘hydrocortisone’/exp OR ‘cortisone’/exp OR ‘predniso-
lone’/exp OR ‘methylprednisolone’/exp OR ‘methylpredni-
solone sodium succinate’/exp OR ‘triamcinolone’/exp OR
‘triamcinolone acetonide’/exp OR ‘budesonide’/exp OR
‘fludrocortisone’/exp OR ‘fluprednisolone’/exp OR ‘para-
methasone’/exp OR glucocortic* OR ‘gluco cortic*’ OR
corticosteroid* OR ‘cortico steroid*’ OR corticoid* OR
steroid* OR corticotropin OR dexamethason* OR dexame-
tason* OR betamethason* OR betametason* OR hydrocor-
tison* OR cortison* OR predniso* OR methylpredniso* OR
‘methyl predniso*’ OR triamcinolon* OR budesonid* OR
fludrocortison* OR fluprednisolon* OR paramethason*
#73. anterior AND (‘cervical spine’/exp OR ‘neck’/exp OR
cervical OR neck) AND (‘intervertebral diskectomy’/exp
OR ‘spinal cord decompression’/exp OR ‘intervertebral
disk’/exp OR ‘intervertebral disk degeneration’/exp OR
‘intervertebral disk hernia’/exp OR ‘radiculopathy’/exp
OR ‘cervical myelopathy’/exp OR discectomy OR diskect-
omy OR decompression OR corpectomy OR radiculopath*
OR myelopath* OR radiculomyelopath* OR ‘radiculo mye-
lopath*’ OR myeloradiculopath* OR ‘myelo radiculopath*’
OR discopath* OR ‘diskitis’/exp OR diskitis OR discitis OR
(disc* OR disk* AND (degenerat* OR displace* OR her-
nia*)) OR ‘anterior spine fusion’/exp OR fusion OR
arthrodesis) AND (‘glucocorticoid’/exp OR ‘steroid’/exp
OR ‘corticosteroid’/exp OR ‘dexamethasone’/exp OR
‘betamethasone’/exp OR ‘hydrocortisone’/exp OR ‘corti-
sone’/exp OR ‘prednisolone’/exp OR ‘methylpredniso-
lone’/exp OR ‘methylprednisolone sodium succinate’/exp
OR ‘triamcinolone’/exp OR ‘triamcinolone acetonide’/exp
OR ‘budesonide’/exp OR ‘fludrocortisone’/exp OR ‘flu-
prednisolone’/exp OR ‘paramethasone’/exp OR glucocor-
tic* OR ‘gluco cortic*’ OR corticosteroid* OR ‘cortico
steroid*’ OR corticoid* OR steroid* OR corticotropin OR
dexamethason* OR dexametason* OR betamethason* OR
betametason* OR hydrocortison* OR cortison* OR pre-
dniso* OR methylpredniso* OR ‘methyl predniso*’ OR
triamcinolon* OR budesonid* OR fludrocortison* OR flu-
prednisolon* OR paramethason*)
OVID
1. Anterior.mp.
2. Cervical Vertebrae/
3. Neck/
4. cervical.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
5. neck.mp. [mp¼title, abstract, original title, name of sub-
stance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supple-
mentary concept word, unique identifier]
6. 2 or 3 or 4 or 5
7. Diskectomy/
8. Decompression, Surgical/
9. Intervertebral Disc/
10. Intervertebral Disc Degeneration/ or Intervertebral Disc
Displacement/
11. Discitis/
12. Radiculopathy/
13. Spinal Cord Diseases/
14. discectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
15. diskectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
16. decompression.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
17. corpectomy.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
18. discitis.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
19. diskitis.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
20. radiculopath*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
21. myelopath*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
22. radiculomyelopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, key-
word heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
23. radiculo-myelopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, key-
word heading word, protocol supplementary concept word,
rare disease supplementary concept word, unique identifier]
24. myeloradiculopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word, key-
word heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identifier]
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25. myelo-radiculopath*.mp. [mp¼title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identifier]
26. discopath*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
27. disc*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
28. disk*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
29. degenerat*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
30. displace*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
31. hernia*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
32. Spinal Fusion/
33. Arthrodesis/
34. fusion.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
35. arthrodesis.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
36. 27 or 28
37. 29 or 30 or 31
38. 36 and 37
39. 7 or 8 or 9 or 10 or 12 or 14 or 15 or 16 or 17 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 32 or 33 or 34 or 35 or 38
40. Glucocorticoids/
41. Adrenal Cortex Hormones/
42. Steroids/
43. Dexamethasone/
44. Betamethasone/
45. Hydrocortisone/
46. Cortisone/
47. Prednisolone/
48. Methylprednisolone/
49. Methylprednisolone Hemisuccinate/
50. Triamcinolone/
51. Triamcinolone Acetonide/
52. Budesonide/
53. Fludrocortisone/
54. Fluprednisolone/
55. Paramethasone/
56. glucocortic*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
57. gluco-cortic*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
58. corticosteroid*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
59. cortico-steroid*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
60. corticoid*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
61. steroid*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
62. corticotropin.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
63. dexamethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
64. dexametason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
65. betamethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
66. betametason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
67. hydrocortison*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
68. cortison*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
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69. predniso*.mp. [mp¼title, abstract, original title, name of
substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
70. methylpredniso*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
71. methyl-predniso*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
72. triamcinolon*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
73. budesonid*.mp. [mp¼title, abstract, original title, name
of substance word, subject heading word, keyword heading
word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
74. fludrocortison*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
75. fluprednisolon*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
76. paramethason*.mp. [mp¼title, abstract, original title,
name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
77. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or
50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60
or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or
71 or 72 or 73 or 74 or 75 or 76
78. 1 and 6 and 39 and 77
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